| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | Form 4 |
| 12 Nov 2026 | 144 |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
1 C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights Cemsidomide Phase 2 MOMENTUM Trial On Track to Complete Enrollment in 1Q 2027 with Initial ORR Data Expected in 2H 2027 Enrollment Complete for... |
| 02 Oct 2026 |
Form 4: Anderson Kenneth Carl, Director
Received 3,662 shares as a grant or award ($11.5K) |
| 02 Oct 2026 |
Form 4: Grogan Donna Roy, Director
Received 4,618 shares as a grant or award ($14.5K) |
| 25 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Protein degraded. Disease targeted. Lives transformed. September 2026 Exhibit 99.2 |
| 21 Sep 2026 |
Form 4: Adams Kendra, Chief Financial Officer
Received 6,250 shares by exercise or conversion · Gave up 2,775 shares to cover exercise price or tax ($9.41K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | 144 |
| 14 Aug 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | 144 |
| 12 Aug 2026 | 144 |
| 12 Aug 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Cemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts in 2027 |
| 27 Jul 2026 | SCHEDULE 13G |
Loading...